Research Collaboration with Soin Neuroscience

Announced: February 13, 2026

Lilac Biosciences announced a strategic research collaboration with Soin Neuroscience, a biotechnology company developing neuromodulation technologies for chronic pain treatment. The collaboration aims to determine whether changes in RNA expression can be used as objective biological markers to measure pain intensity and evaluate how patients respond to neuromodulation therapies.

Key Objectives

• Identify RNA expression signatures associated with chronic pain.
• Study molecular changes before and after neuromodulation treatment.
• Develop quantitative biomarkers that complement patient-reported pain scores.
• Create a biological framework for monitoring treatment effectiveness.

Scientific Importance

Pain assessment today depends largely on subjective scales, such as asking patients to rate pain from 0 to 10. These methods can vary significantly between individuals. Lilac’s RNA analysis platform seeks to introduce measurable biological indicators that provide clinicians with objective evidence of disease state and therapeutic response.

Leadership

The study is being conducted alongside Dr. Amol Soin, founder of Soin Neuroscience and a recognized specialist in interventional pain management and spinal cord stimulation. His clinical expertise complements Lilac’s molecular biology capabilities, creating a translational research partnership between laboratory science and clinical practice.

Strategic Value

For Lilac Biosciences, this collaboration represents an expansion of its RNA analytics platform into the growing field of precision pain medicine, demonstrating how transcriptomic biomarkers could support personalized treatment decisions.